Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Ten years after first collecting an FDA approval, it’s time for version ... obtaining a nod from the FDA in August 2014. The company plans to deliver Cologuard Plus through the same commercial ...

A previous version of this article incorrectly stated that federal regulators inspect imitation weight-loss drugs made by compounding pharmacies. The regulators inspect pharmacy operations but do ...

unless the approved drug is on the FDA’s drug shortage list. However, Hims’ weight-loss injection does not use tirzepatide. Its injection is a compounded form of semaglutide, the medicine sold ...

Zepbound also has been in short supply since being approved less than a year ago as demand for weight-loss drugs has skyrocketed. The FDA’s shortage designation had let compounding pharmacies ...

One alternative may be Wegovy, another FDA-approved drug for weight management ... People must also follow a calorie-restricted diet and an exercise plan while using tirzepatide.

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

The US FDA has approved Bristol Myers ... beginning with today’s approval for schizophrenia.” Bristol Myers Squibb plans to make Cobenfy, a twice-daily pill, available by late October.

The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA ... and next year plans to start ...

The U.S. Food and Drug Administration has approved a new drug for schizophrenia ... which is one of the 15 leading causes of disability worldwide, the FDA reports. Individuals with this disease ...